November | 2012 | Peptonic Medical

Home / 2012 / November

PEPTONIC has raised 13.6 MSEK

- November 1, 2012

PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK. During October 2012 a preference share emission was finished giving 13,6 MSEK. This constituted the possibilities for PEPTONIC

About us

PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.

PEPTONIC has raised 13.6 MSEK

Recent Posts

Recent Comments

Archives

Categories

Meta

All press releases on Spotlightstockmarket.com

About us

Contact us

Dataskyddspolicy

Navigation